The secondary endpoint in the SPARTAN trial was OS, which showed a positive trend; however, the data were premature at the time of data cut-off for the first presentation and publication. 9 QoL was maintained despite the addition of apalutamide to ADT versus placebo which strengthens the actual clinical benefit requirement for patients.
← all excerpts
The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer.
1
—
—